ImmunoGen, Inc. (IMGN): Price and Financial Metrics

ImmunoGen, Inc. (IMGN)

Today's Latest Price: $5.59 USD

0.18 (3.33%)

Updated Oct 29 1:20pm

Add IMGN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

IMGN Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for IMGN is -3.53 -- better than merely 3.18% of US stocks.
  • IMGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 2.96% of US stocks.
  • Revenue growth over the past 12 months for ImmunoGen Inc comes in at 78.37%, a number that bests 93.3% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IMGN, based on their financial statements, market capitalization, and price volatility, are MVIS, WVE, LPTX, BLCM, and RCUS.
  • Visit IMGN's SEC page to see the company's official filings. To visit the company's web site, go to

IMGN Stock Price Chart Interactive Chart >

Price chart for IMGN

IMGN Price/Volume Stats

Current price $5.59 52-week high $7.07
Prev. close $5.41 52-week low $1.95
Day low $5.32 Volume 712,386
Day high $5.63 Avg. volume 2,822,294
50-day MA $4.28 Dividend yield N/A
200-day MA $4.27 Market Cap 975.69M

ImmunoGen, Inc. (IMGN) Company Bio

Immunogen develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company was founded in 1981 and is based in Waltham, Massachusetts.

IMGN Latest News Stream

Event/Time News Detail
Loading, please wait...

IMGN Latest Social Stream

Loading social stream, please wait...

View Full IMGN Social Stream

Latest IMGN News From Around the Web

Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

ImmunoGen's mirvetuximab shows treatment benefit in FRα-positive ovarian cancer

ImmunoGen (IMGN) announces final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and Avastin (bevacizumab) in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive ovarian cancer at the European Society for Medical Oncology ((ESMO)) 2020 Virtual Congress. In the FORWARD II Phase 1b trial,...

Seeking Alpha | September 17, 2020

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

ImmunoGen Presents Final Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin® at ESMO

Business Wire | September 17, 2020

ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference

Business Wire | September 2, 2020

ImmunoGen: High Reward, High Risk

ImmunoGen (IMGN) is a late clinical stage pharmaceutical company with a potential cancer therapy. It was once a relatively high-flyer, with a stock price about 5 times today's, back in July of 2013. That was based largely on early trial data from the drug Mirvetuximab soravtansine, or mirv. This article...

William Meyers on Seeking Alpha | August 4, 2020

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire | August 3, 2020

Read More 'IMGN' Stories Here

IMGN Price Returns

1-mo 57.24%
3-mo 36.01%
6-mo 49.07%
1-year 125.40%
3-year -3.12%
5-year -52.22%
YTD 9.50%
2019 6.35%
2018 -25.12%
2017 214.22%
2016 -84.97%
2015 122.46%

Continue Researching IMGN

Want to see what other sources are saying about ImmunoGen Inc's financials and stock price? Try the links below:

ImmunoGen Inc (IMGN) Stock Price | Nasdaq
ImmunoGen Inc (IMGN) Stock Quote, History and News - Yahoo Finance
ImmunoGen Inc (IMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.803 seconds.